Clinical TrialJul 14, 2026, 02:31 AM
ProMIS Neurosciences PMN310 Shows Dose-Dependent AβO Reduction in Humans
AI Summary
ProMIS Neurosciences announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer’s drug candidate, PMN310. Findings from a Phase 1a trial in healthy volunteers showed a clear reduction in AβO in cerebrospinal fluid at 3 and 29 days post-dosing, representing a significant milestone in Alzheimer's treatment. The company also confirmed it is on track to present six-month blinded interim data from its ongoing Phase 1b trial in the coming weeks, with topline unblinded results anticipated in early Q1 2027.
Key Highlights
- PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers (AβO) in human cerebrospinal fluid.
- Reduction of AβO was observed at both three and 29 days after a single dose in healthy volunteers.
- This represents one of the first quantitative demonstrations of treatment-related oligomer reduction in humans.
- PMN310 showed strict oligomer selectivity, binding to AβO but not monomers, plaques, or vascular deposits.
- The drug candidate exhibited favorable pharmacokinetics and tolerability, with a CSF half-life of approximately 27 days.
- ProMIS Neurosciences is on track to present six-month blinded interim data from its Phase 1b trial in coming weeks.
- Topline unblinded results from the PRECISE-AD Phase 1b trial are expected in early Q1 2027.
- PMN310 received Fast Track Designation from the U.S. FDA in July 2025.
Price Impact
More from PMN